Since 2011, Starboard Value's Jeff Smith has extracted board seats and profits from corporate America — by force if necessary ...
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
Pfizer's stock has struggled due to declining demand for COVID-19 treatments, but activist investor Starboard's $1 billion ...
With one headline, Pfizer had gone from being a well-known hunter — spending heavily to buy rivals — to the hunted.
As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback